Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H23NO2.ClH |
Molecular Weight | 297.82 |
Optical Activity | ( + ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(CO[C@@](CC)(O1)C2=CC=CC=C2)[C@]3([H])CCCCN3
InChI
InChIKey=YXNTVNNAXUKHQM-CLUYDPBTSA-N
InChI=1S/C16H23NO2.ClH/c1-2-16(13-8-4-3-5-9-13)18-12-15(19-16)14-10-6-7-11-17-14;/h3-5,8-9,14-15,17H,2,6-7,10-12H2,1H3;1H/t14-,15+,16-;/m0./s1
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16169732 |
19.8 null [Ki] |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of intravenous anesthetics on continuous avoidance behavior in the rat. | 1976 Feb |
|
Clinical investigation of a new intravenous anesthetic--etoxadrol hydrochloride (CL-1848; U-37862A). | 1976 May-Jun |
|
Discriminative stimulus and reinforcing properties of etoxadrol and dexoxadrol in monkeys. | 1982 Jan |
|
Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist. | 1988 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5921
0.75 mg/kg
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81412
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
20056543
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
23239-37-4
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
C084821
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
DTXSID60945923
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
23239-38-5
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
SUPERSEDED | |||
|
CHEMBL305904
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
OB67QC801N
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | |||
|
m5202
Created by
admin on Fri Dec 15 15:13:06 GMT 2023 , Edited by admin on Fri Dec 15 15:13:06 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD